A new synthetic enzyme, crafted from DNA rather than protein, ‘flips’ lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells.
More research needs to be done to understand whether CRISPR-Cas9 – molecular ‘scissors’ that make gene editing a possibility – may inadvertently increase cancer risk in cells, according to researchers from the University of Cambridge and the Karolinska Institutet.
For women with HER2 positive early-stage breast cancer taking Herceptin for six months could be as effective as 12 months in preventing relapse and death, and can reduce side effects, finds new research.
Transmissible cancers are incredibly rare in nature, yet have arisen in Tasmanian devils on at least two separate occasions. New research from the University of Cambridge identifies key anti-cancer drugs which could be trialled as a treatment for these diseases, which are threatening Tasmanian devils with extinction.
The past few years has seen an explosion in the number of studies using organoids – so-called ‘mini organs’. While they can help scientists understand human biology and disease, some in the field have questioned their usefulness. But as the field matures, we could see their increasing use in personalised and regenerative medicine.
Cambridge University and Institute of Cancer Research launch Children’s Brain Tumour Centre of Excellence22 Feb 2018
Cancer Research UK (CRUK) has today announced funding for a new Children’s Brain Tumour Centre of Excellence, based at the University of Cambridge and The Institute of Cancer Research, London.
The Cancer Research UK Cambridge Centre has become the first UK institute to be designated a Comprehensive Cancer Center of Excellence by the European Academy of Cancer Sciences (EACS).
Kate Gross was just 36 years old when she died of cancer. Researchers at Cambridge – including her husband – are trying to ensure that others receive their diagnoses early enough to stop their cancer.
Scientists have created mini biological models of human primary liver cancers, known as organoids, in the lab for the first time. In a paper published in Nature Medicine, the tiny laboratory models of tumours were used to identify a new drug that could potentially treat certain types of liver cancer.